Søren Rasmussen

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

Mikhail Kosiborod, Steen Z. Abildstrøm, Barry A. Borlaug et al. · New England Journal of Medicine · 2023 · 1.4K citations · Full text

Medicine, Cardiology, Pharmacology +17

Liraglutide and Renal Outcomes in Type 2 Diabetes

Johannes F.E. Mann, David D. Ørsted, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2017 · 1.2K citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +17

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes

Tim Heise, Lidia Hermanski, Leszek Nosek et al. · Diabetes Obesity and Metabolism · 2012 · 399 citations

Medicine, Endocrinology, Pharmacology +17

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

Javed Butler, Sanjiv J. Shah, Mark C. Petrie et al. · The Lancet · 2024 · 323 citations · Full text

Medicine, Cardiology, Pharmacology +10

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials

Mikhail Kosiborod, John Deanfield, Richard Pratley et al. · The Lancet · 2024 · 264 citations

Medicine, Cardiology, Pharmacology +9